Nature communications, 2020-03, Vol.11 (1), p.1187-1187, Article 1187
2020
Details
- Autor(en) / Beteiligte
- Titel
- Escherichia coli adhesion portion FimH functions as an adjuvant for cancer immunotherapy
- Ist Teil von
- Nature communications, 2020-03, Vol.11 (1), p.1187-1187, Article 1187
- Ort / Verlag
- England: Nature Publishing Group
- Erscheinungsjahr
- 2020
- Link zum Volltext
- Quelle
- Alma/SFX Local Collection
- Beschreibungen/Notizen
- Induction of antigen-specific immune activation by the maturation of dendritic cells (DCs) is a strategy used for cancer immunotherapy. In this study, we find that FimH, which is an Escherichia coli adhesion portion, induces toll-like receptor 4-dependent and myeloid differentiation protein 2-independent DC maturation in mice in vivo. A combined treatment regimen with FimH and antigen promotes antigen-specific immune activation, including proliferation of T cells, production of IFN-γ and TNF-α, and infiltration of effector T cells into tumors, which consequently inhibits tumor growth in mice in vivo against melanoma and carcinoma. In addition, combined therapeutic treatment of anti-PD-L1 antibodies and FimH treatment efficiently inhibits CT26 tumor growth in BALB/c mice. Finally, FimH promotes human peripheral blood DC activation and syngeneic T-cell proliferation and activation. Taken together, these findings demonstrate that FimH can be a useful adjuvant for cancer immunotherapy.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 2041-1723eISSN: 2041-1723DOI: 10.1038/s41467-020-15030-4Titel-ID: cdi_doaj_primary_oai_doaj_org_article_ed2a29d550e746acad1fd481acb4d24e
- Format
- –
- Schlagworte
- Adhesins, Escherichia coli - administration & dosage, Adhesins, Escherichia coli - immunology, Adhesion, Adjuvants, Immunologic - administration & dosage, Animals, Antibodies, Antigens, Antineoplastic Agents, Immunological - administration & dosage, Cancer, Cancer immunotherapy, Cell activation, Cell Line, Tumor - transplantation, Cell Proliferation, Combined treatment, Dendritic cells, Dendritic Cells - immunology, Dendritic Cells - metabolism, Disease Models, Animal, E coli, Effector cells, Escherichia coli, Fimbriae Proteins - administration & dosage, Fimbriae Proteins - immunology, Humans, Immune checkpoint, Immunotherapy, Immunotherapy, Adoptive - methods, Lymphocyte Activation, Lymphocytes, Lymphocytes T, Maturation, Melanoma, Metastases, Mice, Neoplasms - immunology, Neoplasms - pathology, Neoplasms - therapy, PD-L1 protein, Peripheral blood, Programmed Cell Death 1 Receptor - antagonists & inhibitors, Programmed Cell Death 1 Receptor - immunology, Receptors, Chimeric Antigen - immunology, Recombinant Proteins - administration & dosage, Recombinant Proteins - immunology, T-Lymphocytes - immunology, TLR4 protein, Toll-Like Receptor 4 - metabolism, Toll-like receptors, Tumor necrosis factor-α, Tumors, γ-Interferon